Loading…
REGENXBIO Inc. is projected to rise to $9.85 by 2027, a +47% move from its current price of $6.69. RGNX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.38 | $6.70 | $7.04 | +0.17% |
| May 30 | $6.26 | $6.71 | $7.19 | +0.35% |
| May 31 | $6.18 | $6.72 | $7.32 | +0.52% |
| Jun 1 | $6.11 | $6.74 | $7.43 | +0.69% |
| Jun 2 | $6.05 | $6.75 | $7.53 | +0.87% |
| Jun 3 | $6.00 | $6.76 | $7.62 | +1.04% |
| Jun 4 | $5.95 | $6.77 | $7.71 | +1.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.95 | $6.77 | $7.71 | +1.22% |
| Week 2 | $5.71 | $6.85 | $8.23 | +2.45% |
| Week 3 | $5.54 | $6.94 | $8.68 | +3.70% |
| Week 4 | $5.42 | $7.02 | $9.10 | +4.96% |
| Week 5 | $5.32 | $7.11 | $9.49 | +6.24% |
| Week 6 | $5.24 | $7.19 | $9.88 | +7.53% |
| Week 7 | $5.17 | $7.28 | $10.25 | +8.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
REGENXBIO Inc. is a clinical-stage biotechnology company that focuses on gene therapies designed to deliver functional genes to cells with genetic defects in the United States. Its work centers on NAV Technology Platform, a proprietary adeno-associated virus gene delivery system that underpins its candidate therapies.
The company’s pipeline includes ABBV-RGX-314 for wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; RGX-202 for Duchenne muscular dystrophy; RGX-121 for mucopolysaccharidosis type II; and RGX-111 for mucopolysaccharidosis type I. REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical firms and has collaboration and license agreements with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd.
to develop RGX-121 and RGX-111 outside the United States.
Incorporated in 2008 and headquartered in Rockville, Maryland, REGENXBIO operates within the healthcare sector, delivering gene therapies through its proprietary platform and pipeline.”
REGENXBIO Inc. is a healthcare company trading as RGNX with a current price of $6.35 and a market capitalization of $328.28M. It ranks 3432 by market cap.
The stock’s 30-day range spans $4.55 to $8.85, and the current price sits within this range as investors evaluate the growth potential of its gene-therapy platform and pipeline.
The forecasted price trajectory shows a bullish tilt beyond 2026, with a progression of average prices from $6.35 in 2026 to higher levels in later years, including a long-term rise to an average of $30.67 by 2050 and a maximum forecast of $70.54.”
A major floor 59.2% below — a decisive break under it would weaken the trend.
The nearest floor, 15.5% below — buyers have tended to step in here.
The nearest ceiling, 57.7% above — a clean break opens room to run.
A major ceiling 138.9% above — clearing it would confirm fresh momentum.
Key RGNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.41 | Buy | $6.50 | Buy |
| MA 10 | $6.54 | Buy | $6.88 | Sell |
| MA 20 | $8.10 | Sell | $7.57 | Sell |
| MA 50 | $8.45 | Sell | $8.45 | Sell |
| MA 100 | $9.73 | Sell | $9.27 | Sell |
| MA 200 | $10.49 | Sell | $9.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.73 | Neutral |
| Stoch RSI (14) | 32.48 | Neutral |
| CCI (20) | -53.54 | Neutral |
| Williams %R (14) | -78.78 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | -36.59 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 21.22 | Neutral |
| TRIX (15) | -0.85 | Sell |
| Awesome (5,34) | -2.09 | Sell |
| Ultimate (7,14,28) | 55.64 | Neutral |
| Momentum (10) | -3.55 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 6.58 | Buy |
| ADX (14) | 24.53 | Sell |
| ATR (14) | 0.44 | Info |
The 30-day technical picture is Bearish, with RSI14 at 40 and sentiment labeled as BEARISH.
The stock’s 50-day simple moving average is $8.54, while the 200-day simple moving average sits at $10.50, indicating price momentum tracking below longer-term averages.
Support is identified at $5.65 and resistance at $10.55. Over the last 30 days, the price has traded within a range of $4.55 to $8.85, highlighting near-term volatility. Annualized volatility stands at 100%, underscoring elevated risk and potential price swings.”
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.65 | $6.69 | $11.27 | 0% | Neutral | |
| $7.21 | $9.85 | $14.52 | +47% | Bullish | |
| $8.54 | $12.30 | $19.21 | +84% | Bullish | |
| $7.84 | $11.83 | $19.32 | +77% | Bullish | |
| $6.60 | $10.37 | $17.58 | +55% | Bullish | |
| $7.01 | $11.46 | $20.05 | +71% | Bullish | |
| $6.52 | $11.05 | $19.90 | +65% | Bullish | |
| $7.93 | $13.93 | $25.72 | +108% | Bullish | |
| $9.77 | $17.76 | $33.58 | +165% | Bullish | |
| $8.64 | $16.23 | $31.37 | +143% | Bullish | |
| $10.85 | $23.94 | $50.57 | +258% | Bullish | |
| $16.21 | $36.02 | $82.85 | +438% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.65 | $6.69 | $7.91 | +0.00% |
| June 2026 | $5.90 | $7.05 | $8.71 | +5.38% |
| July 2026 | $6.45 | $7.83 | $9.91 | +11.10% |
| August 2026 | $6.47 | $7.95 | $10.23 | +1.46% |
| September 2026 | $6.36 | $7.89 | $10.30 | -0.74% |
| October 2026 | $6.72 | $8.41 | $11.13 | +6.65% |
| November 2026 | $6.89 | $8.70 | $11.64 | +3.41% |
| December 2026 | $6.55 | $8.34 | $11.27 | -4.19% |
Click any year to see its month-by-month RGNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RGNX is projected to trade between $5.65 and $11.27, averaging $6.69 — a potential gain of 0% from today's $6.69. Price action looks broadly range-bound.
REGENXBIO Inc.'s 2027 outlook centres on $9.85, within a $7.21 to $14.52 range. That is up +47% on the projected 2026 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, RGNX could reach as high as $19.21, with a base case around $12.30 and support toward $8.54 — roughly +84% from $6.69. Momentum favours further upside here.
Expect RGNX to range from $7.84 to $19.32 through 2029. The $11.83 average target implies a +77% move from current prices. That is -4% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The RGNX price prediction for 2030 points to an average of $10.37 (low $6.60, high $17.58) — a potential gain of +55% on today's $6.69. Momentum favours further upside here.
In 2031, RGNX is projected to trade between $7.01 and $20.05, averaging $11.46 — a potential gain of +71% from today's $6.69. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
REGENXBIO Inc.'s 2032 outlook centres on $11.05, within a $6.52 to $19.90 range. That is -4% versus the projected 2031 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2033, RGNX could reach as high as $25.72, with a base case around $13.93 and support toward $7.93 — roughly +108% from $6.69. Buyers look set to stay in control over this stretch.
Expect RGNX to range from $9.77 to $33.58 through 2034. The $17.76 average target implies a +165% move from current prices. That is up +28% on the projected 2033 average. Momentum favours further upside here.
The RGNX price prediction for 2035 points to an average of $16.23 (low $8.64, high $31.37) — a potential gain of +143% on today's $6.69. Buyers look set to stay in control over this stretch.
In 2040, RGNX is projected to trade between $10.85 and $50.57, averaging $23.94 — a potential gain of +258% from today's $6.69. That is up +47% on the projected 2035 average. Momentum favours further upside here.
REGENXBIO Inc.'s 2050 outlook centres on $36.02, within a $16.21 to $82.85 range. That is up +50% on the projected 2040 average. That marks a +438% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RGNX today (≈ 149.476831 RGNX) could be worth
$5,384.44
+$4,384.44 (+438%) by 2050 · US Dollar
Based on the average projected RGNX price of $36.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGNXwould be worth at today's price.
$1,000 invested in RGNX on May 27, 2025 (≈ 110.253587 RGNX) would be worth
$737.6
-$262.4 (-26.2%) today · 0.74× · US Dollar
Based on a RGNX entry price of $9.07 vs. today's $6.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.97 | $1,120.6 | +12.1% |
| 1 month ago | $8.62 | $776.1 | -22.4% |
| 3 months ago | $8.75 | $764.57 | -23.5% |
| 6 months ago | $13.39 | $499.63 | -50.0% |
| 1 year ago | $9.07 | $737.6 | -26.2% |
| All time (5.0y) ago | $35.75 | $187.13 | -81.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGNX forecast.
Our base-case forecast reaches $13.00 around 2033.
Implied market cap at $13.00: $672.07M
The multi-year forecast points to a bullish trajectory for REGENXBIO, with the average price climbing across several years and substantial upside in later years.
In 2027, the average price is projected at $9.28 with a 46.1% implied ROI, followed by $11.54 in 2028 (81.8% ROI) and $10.97 in 2029 (72.7% ROI). By 2030 the average is $9.62 with a 51.4% ROI, and in 2031 the average rises to $10.42 (64.1% ROI). The 2032 estimate is $9.81 (54.5% ROI), and 2033 is $12.23 (92.7% ROI).
Further out, 2034 shows an average of $15.71 (147.4% ROI) and 2035 of $14.41 (126.9% ROI). The forecast then extends to 2040 with an average of $20.48 (222.5% ROI) and culminates in 2050 with an average of $30.67 (383% ROI) and a max of $70.54.
These figures reflect estimates rather than guarantees and depend on multiple factors including clinical progress, regulatory outcomes, and market dynamics. Investors should consider the inherent uncertainty and risks in such long-horizon projections.”
Tap a question to reveal the answer.
In 2030, the forecasted average price is $9.62, with a minimum of $6.04 and a maximum of $16.46; ROI is 51.4 and sentiment is BULLISH.
The forecast shows bullish sentiment in 2027 through 2050, with rising average prices and positive ROI in multiple years. The 2026 forecast is neutral, indicating some near-term uncertainty.
Yes. The 2050 forecast maximum is $70.54, reflecting significant upside potential in the long term.
The current price is $6.35 and the market capitalization is $328.28M.
The 30-day picture is Bearish with RSI 14 at 40. The 50-day SMA is $8.54 and the 200-day SMA is $10.50, with support at $5.65 and resistance at $10.55. The 30-day range is $4.55 to $8.85, and annualized volatility is 100%.
REGENXBIO Inc. Community Discussion
0Share your REGENXBIO Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.